摘要
探讨EGFR-TKI治疗＂窗口期＂联合放疗治疗局部大肿块非小细胞肺癌的可行性。分析2011年6月-2015年6月收治的非小细胞肺癌患者10例,均为EGFR基因突变阳性的局部大肿块,首先行TKI治疗,在其＂窗口期＂内给予恰当的放疗,并评估疗效。结果：（1）TKI治疗1个月后,10例患者肺部肿瘤均不同程度缩小,随即4例完成了常规放疗,6例完成了体部立体定向放射治疗;（2）放疗结束1个月后评估,CR 2例,PR 8例,不良反应可耐受;（3）至随访结束,6例出现耐药,中位PFS为28个月（范围为13个月-33个月）。TKI治疗＂窗口期＂联合放疗治疗局部大肿块非小细胞肺癌,可增加根治性放疗的机会,并有延缓TKI耐药的可能,值得进一步研究。
To investigate the feasibility of EGFR-TKI combined with radiotherapy in the treatment of non-small cell lung cancer with localized large pulmonary mass during EGFR-TKI treatment ＂ window period＂,the authors analyzed 10 cases of non-small cell lung cancer from June of 2011 to 2015 which were all EGFR-mutated patients with locally large pulmonary mass.All cases were firstly treated with TKI,and then treated with radiotherapy within the TKI treatment ＂window period＂,and the therapeutic effect was evaluated.（1）After a month of TKI treatment,the tumors of the 10 patients were evaluated to be more or less decreased.Then 4 cases accepted conventional radiotherapy,6cases accepted stereotactic body radiotherapy;（2）1 month after the end of radiotherapy,2 cases was evaluated to CR,8 cases was evaluated to PR,and toxicities were generally tolerated;（3）Until the end the follow-up,6cases out of 10 got drugresistance,their median PFS was 28 months（range,13 months-33 months）.The combination of radiotherapy and TKI during the ＂ window period＂ can increase the opportunities of radical radiotherapy for localized large mass of non-small cell lung cancer patients,and may decrease the chance of drug resistance.It＇s a problem worth studying.
出处
《医学与哲学（B）》
2016年第5期42-45,共4页
Medicine & Philosophy(B)
基金
2012年度宜宾市"一抓一"100万科技工程项目
项目编号:2012ZSF007
2013年度宜宾市重点科技计划项目资金
项目编号:2013SF011
关键词
非小细胞肺癌
表皮生长因子受体-酪氨酸激酶抑制剂
放疗
窗口期
non-small cell lung cancer
epidermal growth factor receptor-tyrosine kinase inhibitor
radiotherapy
window period
